Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinical trial results registries may contain relevant unpublished information. Our main aim was to investigate the potential impact of the inclusion of reports from industry results registries on systematic reviews (SRs). METHODS: We identified a sample of 150 eligible SRs in PubMed via backward selection. Eligible SRs investigated randomized controlled trials of drugs and included at least 2 bibliographic databases (original search date: 11/2009). We checked whether results registries of manufacturers and/or industry associations had also been searched. If not, we searched these registries for additional trials not considered in the SRs, as well as for additional data on trials already considered. We reanalysed the primary outcome and harm outcomes reported in the SRs and determined whether results had changed. A "change" was defined as either a new relevant result or a change in the statistical significance of an existing result. We performed a search update in 8/2013 and identified a sample of 20 eligible SRs to determine whether mandatory results registration from 9/2008 onwards in the public trial and results registry ClinicalTrials.gov had led to its inclusion as a standard information source in SRs, and whether the inclusion rate of industry results registries had changed. RESULTS: 133 of the 150 SRs (89%) in the original analysis did not search industry results registries. For 23 (17%) of these SRs we found 25 additional trials and additional data on 31 trials already included in the SRs. This additional information was found for more than twice as many SRs of drugs approved from 2000 as approved beforehand. The inclusion of the additional trials and data yielded changes in existing results or the addition of new results for 6 of the 23 SRs. Of the 20 SRs retrieved in the search update, 8 considered ClinicalTrials.gov or a meta-registry linking to ClinicalTrials.gov, and 1 considered an industry results registry. CONCLUSION: The inclusion of industry and public results registries as an information source in SRs is still insufficient and may result in publication and outcome reporting bias. In addition to an essential search in ClinicalTrials.gov, authors of SRs should consider searching industry results registries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the health sciences, study registries (Table 2) allow researchers to locate ongoing clinical trials and studies that may have gone unpublished [54 -56].”
From PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews (2021) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“reviews and Meta-Analyses (PRISMA) Statement, also recommends searching trial registries [54].”
BackgroundEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“Both our study and the meta-analysis of rosiglitazone trials already cited [20] refer to the impact of industry results registries; similar findings have been shown for public sources.”
ResultSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Epidemiology and reporting characteristics of systematic reviews.
Moher, D., Tetzlaff, J., Tricco, A. C., Sampson, M., & Altman, D. G. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040078 · Cited by 891 · cited 1×
“Cochrane reviews are generally of better reporting quality and typically search substantially more databases than non- Cochrane reviews [50]; in addition, the Cochrane Handbook acknowledges the increasing importance of searching trial registries [51].”
BackgroundPublication bias: the case for an international registry of clinical trials.
Simes, R. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1529 · Cited by 747 · cited 1×
“As early as 1986, Simes compared results of published cancer trials and trials identified in the International Research Cancer Databank [4].”
ResultMelander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 635
Chan, A.-W., & Altman, D. G. (2005) · BMJ · doi:10.1136/bmj.38356.424606.8f · Cited by 613
Grey literature in meta-analyses of randomized trials of health care interventions
Hopewell, S., McDonald, S., Clarke, M. J., & Egger, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000010.pub3 · Cited by 598
Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 588
Self-citationLefebvre, C., Manheimer, E., & Glanville, J. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch6 · Cited by 559 · cited 1×
“Cochrane reviews are generally of better reporting quality and typically search substantially more databases than non- Cochrane reviews [50]; in addition, the Cochrane Handbook acknowledges the increasing importance of searching trial registries [51].”
Dickersin, K. (2003) · JAMA · doi:10.1001/jama.290.4.516 · Cited by 512
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452 · cited 2×
“On the part of the pharmaceutical industry, as early as 2002 the US member companies of the Pharmaceutical Research and Manufacturers Association committed themselves to the registration of all hypothesis-testing clinical trials at initiation and also to the timely disclosure of summary results, regardless of outcome…”
BackgroundSelf-citationJørgensen, A. W., Hilden, J., & Gøtzsche, P. C. (2006) · BMJ · doi:10.1136/bmj.38973.444699.0b · Cited by 444
Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., & Krumholz, H. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000144 · Cited by 401 · cited 1×
“gov and completed prior to January 2006 were published 2 years after completion [45].”
BackgroundOutcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0906126 · Cited by 361 · cited 1×
“The registration of trial protocols (including any amendments) and of full results can help to identify this type of bias [40,41] and is also called for in the Ottawa statement [6].”
BackgroundNon-publication of large randomized clinical trials: cross sectional analysis
Jones, C. W., Handler, L., Crowell, K. E., Keil, L. G., Weaver, M. A., & Platts-Mills, T. F. (2013) · BMJ · doi:10.1136/bmj.f6104 · Cited by 350
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub2 · Cited by 305 · cited 3×
“Cipriani 2009 [29] HAM-D failure to respond HAM-D failure to respond Treatment-emergent AEs Treatment-emergent AEs Primary outcome”
BackgroundResultSertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Angelis, C. D., Drazen, J. M., Frizelle, F. A., Haug, C. J., Hoey, J., Horton, R., Kotzin, S., Laine, C. M., Marušić, A., Overbeke, A. J. P. M., et al. (2004) · PubMed · Cited by 275
Krleža-Jerić, K., Chan, A.-W., Dickersin, K., Sim, I., Grimshaw, J., & Gluud, C. (2005) · BMJ · doi:10.1136/bmj.330.7497.956 · Cited by 236
Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial
Berkowitz, R. I., Fujioka, K., Daniels, S. R., Hoppin, A. G., Owen, S., Perry, A. C., Sothern, M. S., Renz, C. L., Pirner, M. A., Walch, J. K., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-2-200607180-00005 · Cited by 220
Wang, Y., Xia, J., Helfer, B., Li, C., & Leucht, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004028.pub4 · Cited by 183 · cited 2×
“Two of these changes were to the disadvantage of the test drug for an SR of valproate in schizophrenia (adverse event rate) [27] and for an SR of sibutramine in obesity (blood pressure values) [26].”
BackgroundMethodClinical trial registration: transparency is the watchword
Sim, I., Chan, A.-W., Gülmezoglu, A. M., Evans, T., & Pang, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68708-4 · Cited by 165
Grey literature in meta-analyses of randomized trials of health care interventions
Hopewell, S., McDonald, S., Clarke, M., & Egger, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000010.pub2 · Cited by 137
Wieseler, B., Kerekes, M. F., Vervoelgyi, V., McGauran, N., & Kaiser, T. (2012) · BMJ · doi:10.1136/bmj.d8141 · Cited by 129 · cited 1×
“In 2012 we published a comparison of the completeness of reporting of information sources used for 268 trials included in 16 SRs of drugs prepared between 2006 and February 2011 [31].”
MethodSelf-citationWieseler, B., Wolfram, N., McGauran, N., Kerekes, M. F., Vervölgyi, V., Kohlepp, P., Kamphuis, M., & Grouven, U. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001526 · Cited by 129 · cited 1×
“A second recently published analysis of a subsample of the above trials also showed major discrepancies between all 3 information sources regarding the completeness of reporting of several (both primary and secondary) patient-relevant outcomes such as clinical events and symptoms, quality of life, and adverse events […”
ResultSelf-citationLaine, C., Horton, R., DeAngelis, C. D., Drazen, J. M., Frizelle, F. A., Godlee, F., Haug, C., Hébert, P. C., Kotzin, S., Marusic, A., et al. (2007) · BMJ · doi:10.1136/bmj.39233.510810.80 · Cited by 98
Progress and Deficiencies in the Registration of Clinical Trials
Wood, A. J. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmsr0806582 · Cited by 78 · cited 1×
“gov, as mandatory posting of results according to the FDA Amendments Act did not apply to trials completed prior to 27 September 2007, and a 12-month time lag for posting applied to trials completed afterwards [10,24].”
MethodRasmussen, N., Lee, K., & Bero, L. (2009) · Trials · doi:10.1186/1745-6215-10-116 · Cited by 62
Moja, L. P., Moschetti, I., Nurbhai, M., Compagnoni, A., Liberati, A., Grimshaw, J. M., Chan, A.-W., Dickersin, K., Krleza-Jeric, K., Moher, D., et al. (2009) · Trials · doi:10.1186/1745-6215-10-56 · Cited by 62 · cited 1×
“Secondly, even if a trial is registered, the information provided may be inadequate: a retrospective evaluation of 21 industry and public trial registries showed that, although compliance with the registration criteria of the World Health Organization had improved between the years 2005 and 2007, individual registry e…”
BackgroundEzetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation
Ara, R., Tumur, I., Pandor, A., Duenas, A., Williams, R., Wilkinson, A., Paisley, S., & Chilcott, J. (2008) · Health Technology Assessment · doi:10.3310/hta12210 · Cited by 60 · cited 2×
“Finally, we identified additional data for a comparison of adverse event rates reported in an SR on ezetimibe in hypercholesterolaemia [30].”
ResultSchwarz, C., Volz, A., Li, C., & Leucht, S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004028.pub3 · Cited by 60
Milnacipran versus other antidepressive agents for depression
Nakagawa, A., Watanabe, N., Omori, I. M., Barbui, C., Cipriani, A., McGuire, H., Churchill, R., & Furukawa, T. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006529.pub2 · Cited by 56 · cited 3×
“An SR of milnacipran [28] contained no data on milnacipran versus venlafaxine: we identified a trial that reported both efficacy and safety data for this comparison.”
BackgroundSearching for unpublished data for Cochrane reviews: cross sectional study
Schroll, J. B., Bero, L., & Gotzsche, P. C. (2013) · BMJ · doi:10.1136/bmj.f2231 · Cited by 43 · cited 1×
“However, less than 40% of Cochrane reviews have been shown to search trial registries [52] and a recent survey of over 2000 Cochrane authors reported that only about 6% and 1% obtained unpublished data from public and industry registries respectively [53].”
BackgroundOlanzapine in long-term treatment for bipolar disorder
Cipriani, A., Rendell, J. M., & Geddes, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004367.pub2 · Cited by 38 · cited 2×
“Cipriani 2009 [25] Recurrence of any affective episode Relapse mania or depression Withdrawals due to AE Withdrawals due to AE Primary outcome”
BackgroundMandatory disclosure of trial results for drugs and devices
Groves, T. (2008) · BMJ · doi:10.1136/bmj.39469.465139.80 · Cited by 29
Identification of Additional Trials in Prospective Trial Registers for Cochrane Systematic Reviews
van Enst, W. A., Scholten, R. J. P. M., & Hooft, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042812 · Cited by 24
Milnacipran versus other anti-depressive agents for depression
Nakagawa, A., Watanabe, N., Omori, I. M., Cipriani, A., Barbui, C., McGuire, H., Churchill, R. C., Furukawa, T. A., & Ant, M.-A. O. N. G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006529 · Cited by 16
Closing a Loophole in the FDA Amendments Act
Turner, E. H., Moaleji, N., & Arnold, B. L. (2008) · Science · doi:10.1126/science.322.5898.44c · Cited by 15 · cited 1×
“Furthermore, the Act contains a major loophole, as it was prospective and thus does not cover trials of many drugs widely prescribed in clinical practice [35].”
BackgroundCan sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis
Júnior, H. P. D. L., Atallah, Á. N., & Lemos, A. L. A. (2008) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802008000600010 · Cited by 6 · cited 2×
“deLemos 2008 [26] Systolic blood pressure Systolic blood pressure No safety outcome was reported in the SR No safety outcome was reported in the SR Primary outcome”
BackgroundSibutramine for obesity in adolescents
Doggrell, S. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.17.2435 · Cited by 4
Deaths in trials should always be reported
Schroll, J. B. (2013) · BMJ · doi:10.1136/bmj.f4219 · Cited by 2 · cited 1×
“recently published comparison of internal company synopses and journal publications on trials of the oral antidiabetic repaglinide showed that, in addition to other inconsistencies, the reporting of deaths was incomplete in both types of documents [36].”
Result
Research works printed but not linked: 2
- Food and Drug Administration, editor (2011) Approved drug products with therapeutic equivalence evaluations: 31st edition. Rockville: FDA.
- A Jack, 2013, Pharma group sues European regulator over data, Financial Times
Cited by
Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., Koffel, J. B., PRISMA-S Group, Blunt, H., Brigham, T., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-020-01542-z · Cited by 3,714
Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., & Koffel, J. (2019) · doi:10.31219/osf.io/sfc38 · Cited by 3,696
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., Koffel, J. B., & Group, P.-S. (2021) · Journal of the Medical Library Association · doi:10.5195/jmla.2021.962 · Cited by 409
Golder, S., Loke, Y. K., Wright, K., & Norman, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002127 · Cited by 277
“There were also two systematic reviews identified in Potthast 2014 [33] in which unpublished additional trial data led to a new comparison not reported in the systematic reviews, which could not be represented here.”
Background
Metadata
- Authors
- Potthast, R., Vervölgyi, V., McGauran, N., Kerekes, M. F., Wieseler, B., & Kaiser, T.
- Affiliations
- Institute for Quality and Efficiency in Health Care (DE)
- Corresponding author
- Potthast, Regine
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-17
- Volume
- 9
- Issue
- 4
- Pages
- e92067
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3990559
- OpenAlex
- W2070949203
- Cited by
- 20
- References
- 46
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 1 · 2021: 4 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 1
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- systematic review search strategy, ClinicalTrials.gov, unpublished trials, publication bias, selective reporting, drug trials
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Registries, Review Literature as Topic, PubMed, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
